Nomura Y, Yamagata J, Kondo H
Gan. 1979 Aug;70(4):473-82.
In 36 patients with advanced breast cancer, most of whom had been subjected to major endocrine ablation therapy such as bilateral adrenalectomy, correlation between the presence or absence of estrogen receptor (ER) in tumors and response to chemotherapy was investigated. Complete or partial response was obtained in 6 of 14 (42.6%) patients with ER-positive tumors and in 3 of 22 (13.6%) patients with ER-negative tumors (P = 0.1). The response to chemotherapy was not influenced by the concentration of ER in tumors. Distribution of the duration of regression readings and the survival time was not significantly different between the patients with ER-positive and -negative tumors. Some regimens which did not include adriamycin, such as MFC (mitomycin-C, 5-fluorouracil, and cytosine arabinoside) had a good effect on the ER-positive cases, whereas the response to regimens including adriamycin was not influenced by the ER positiveness of the tumors. In the classification of some clinical parameters of the patients, response of the patients with ER-negative tumors does not seem to be better than that of the patients with ER-positive tumors. Responses to the major endocrine ablation therapy and also to the subsequently carried out chemotherapy were influenced by the presence or absence of ER in tumors before the endocrine therapy.
在36例晚期乳腺癌患者中，大多数患者已接受过双侧肾上腺切除术等主要内分泌消融治疗，研究了肿瘤中雌激素受体（ER）的有无与化疗反应之间的相关性。14例ER阳性肿瘤患者中有6例（42.6%）获得完全或部分缓解，22例ER阴性肿瘤患者中有3例（13.6%）获得完全或部分缓解（P = 0.1）。化疗反应不受肿瘤中ER浓度的影响。ER阳性和阴性肿瘤患者的缓解持续时间和生存时间分布无显著差异。一些不包括阿霉素的方案，如MFC（丝裂霉素-C、5-氟尿嘧啶和阿糖胞苷）对ER阳性病例有良好效果，而含阿霉素方案的反应不受肿瘤ER阳性状态的影响。在对患者的一些临床参数进行分类时，ER阴性肿瘤患者的反应似乎并不优于ER阳性肿瘤患者。内分泌治疗前肿瘤中ER的有无会影响对主要内分泌消融治疗以及随后进行的化疗的反应。
